Please login to the form below

Not currently logged in
Email:
Password:

Royalty Pharma mulls bid for Elan

Follows Biogen’s $3.25bn acquisition of Tysabri from Elan

Royalty PharmaFresh from negotiating a $3.25bn windfall from partner Biogen Idec, Elan has become the target of a possible takeover bid by US company Royalty Pharma.

Privately-held Royalty Pharma specialises in buying up intellectual property assets in the pharma sector, generating revenues from royalty interests in more than 30 approved or late-stage drugs.

The company's move for Elan comes after the Irish drugmaker signed over rights to multiple sclerosis therapy Tysabri (natalizumab) to Biogen Idec in a deal that netted it $3.25bn upfront and a royalty steam.

Elan has already said it would return $1bn to shareholders and refinance debt, with analysts suggesting that a push for liquidity meant some form of merger or acquisition may be on the cards.

Royalty Pharma said in a statement issued this morning that it met with Elan's management last week to propose a $11-per-share offer for the pharma company - a 12.5 per cent premium to its closing price on February 15 - and was "surprised" that Elan's subsequent statement about the Biogen Idec deal had made no mention of its approach.

The offer would value Elan at more than $6bn but is only around 4 per cent higher than the company's closing share price last Friday of $10.58.

The company said it was effectively offering Elan shareholders a "simple and clear choice": remain an investor in a company whose material assets will consist of cash and Tysabri royalties while management looks for other opportunities, or sell for a cash amount.

"The risks and lack of earnings visibility associated with Elan's acquisition and in-licensing strategy are substantial," claims Royalty Pharma in its proposal document, which stresses this is not yet a firm intention to make an offer.

At the time of writing Elan had not yet responded publicly to the proposal statement from Royalty Pharma.

25th February 2013

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

AI and life sciences
AI: the smart money is on the smart thinking
Looking at the three key areas where AI is being applied: drug discovery, clinical decision-making and clinical trials...
Virtual Engagement At Porterhouse: Reflections on the past few months
A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
July 2020: diversity and inclusion in clinical trials round-up
COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...

Infographics